About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Cipla Urged by Voluntary Group to Reduce AIDS Drug Price

by VR Sreeraman on August 24, 2007 at 8:02 PM
Font : A-A+

Cipla Urged by Voluntary Group to Reduce AIDS Drug Price

An international voluntary group active in treating HIV/AIDS patients Friday appealed to pharma major Cipla to reduce the price of AIDS drugs.

The US-based AIDS Healthcare Foundation said that out of the 2.5 million Indians suffering from HIV/AIDS, 85,000 are receiving antiretroviral treatment.

Advertisement

Quoting Médecins Sans Frontières, an international medical and humanitarian aid organisation, the foundation claimed that Cipla provides African countries with AIDS drugs much cheaper than it provides to Indians.

"While Cipla offers African nations the same drug for Rs.21,200 (per person per year), it is available in India for Rs.54,000," said Chinkholal Thansing, Asia Pacific bureau chief of the foundation.
Advertisement

The organisation said the per capita gross national income (GNI) in India was roughly $730, while Cipla's published price in India for the AIDS drug Viraday was around $1,344, nearly twice the average Indian's annual income.

In this connection, the AIDS Healthcare Foundation (AHF) had published an advertisement in a number of newspapers. Reacting to this Cipla had already sent a legal notice to AHF asking it to publish a public apology or else face a defamation case worth $25 million.

"We are a voluntary group and have no rivalry with Cipla. Though we appreciate Cipla for developing antiretroviral drugs but we will not apologise to it," Thansing said.

Source: IANS
SRM/B
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Oral Health And AIDS Drug Toxicity AIDS/HIV AIDS/HIV - Epidemiology AIDS/HIV - Clinical Features AIDS/HIV - Health Education AIDS/HIV - Prevention And Transmission AIDS / HIV - Treatment AIDS/HIV- Lab Tests and Faqs AIDS - Initial Theories and Disease Progression 

Recommended Reading
AIDS / HIV - Treatment
Encyclopedia section of medindia explains in brief about the treatment for AIDS/HIV...
US FDA Approves First in New Class of HIV Drug
Pfizer's maraviroc, the first in a new class of HIV drugs formulated to stop HIV virus from ......
AIDS - Initial Theories and Disease Progression
AIDS was first detected in early 1980s, among gays, Haitians and black Africans. HIV is a descendant...
AIDS/HIV
"AIDS is an epidemic disease, a potentially preventable, deadly infection for which there is no cure...
AIDS/HIV - Clinical Features
Encyclopedia section of medindia gives general info about HIV Clinical Features...
AIDS/HIV - Epidemiology
AIDS or HIV is an epidemic disease, a potentially deadly infection that can be prevented with preca...
AIDS/HIV - Health Education
Encyclopedia section of medindia gives general info about AIDS information and health education....
AIDS/HIV - Prevention And Transmission
Encyclopedia section of medindia explains in brief about the prevention for AIDS/HIV...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Oral Health And AIDS
AIDS has taken on massive proportions in modern times. It is estimated that over 15 million people a...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use